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CC BY-NC-ND license (http://creativeAbstract Alternative eradication therapies for Helicobacter pylori infection are needed
because of an increasing failure rate over the past decade. The aim of this study was to deter-
mine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing
proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for
573 patients who underwent primary H. pylori eradication therapy were retrospectively re-
viewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-
suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg
(EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week. Eradication was successful in 73%
(419/573) of patients using intention-to-treat (ITT) analysis and 76% (419/549) of patients in
per-protocol (PP) analysis. The VAC group had a significantly superior eradication rate
compared with the LAC and RAC groups in ITT (VAC 83%, LAC 66% and RAC 67%, p < 0.01)
and PP analysis (VAC 85%, LAC 69% and RAC 70%, p < 0.01), and had a similarly high eradication
rate to the EAC group (83% in ITT and 87% in PP). Although the eradication rate in the VAC and
EAC groups was not significantly higher than in the LAC and RAC groups in patients with mild
gastric atrophy with both ITT and PP analyses, it was significantly higher in patients with severe
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256 S. Shinozaki et al.than the LAC and RAC groups, and a > 80% eradication rate regardless of the degree of atrophy.
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Curative therapy for Helicobacter pylori infection has
become a major interest for gastroenterologists over the
past 2 decades, because eradication of H. pylori decreases
the incidence of future gastric cancer as well as gastroduo-
denal ulcers [1]. In Japan, standard triple therapy has been
approved for the treatment ofH.pylori-infectedpeptic ulcer
by the national health insurance system since 2000, and
consists of using a proton pump inhibitor (PPI) with amoxi-
cillin and clarithromycin twice daily for 1week. At that time,
three kinds of PPIs including omeprazole, lansoprazole, and
rabeprazole were available in Japan. In 2013, the Japanese
health insurance system began reimbursement for primary
H. pylori eradication therapy in patients with H. pylori
gastritis diagnosed by esophagogastroduodenoscopy (EGD).
Since that time, thenumber of patients receiving eradication
therapy has been increasing.
However, the primary H. pylori eradication rate has been
decreasing to an unacceptable level over the past decade
[2,3]. The recent subsequent increase in bacterial resistance
to clarithromycin in Japan led to a decline in successful
eradication using first-line therapy [4]. Therefore, a novel
strategy for primary H. pylori eradication has been sought.
Esomeprazole (an S-isomer of omeprazole), a second gener-
ation PPI, suppresses gastric acid secretion more strongly,
resulting in improved susceptibility to antibiotics byH.pylori.
In 2011, this drug was released in Japan and made available
forH. pylori eradication therapy. Ameta-analysis showed the
superiority of esomeprazole in the primary eradication of H.
pylori compared with other PPIs [5]. In 2015, vonoprazan, a
member of a new class of potassium-competitive acid
blockers (P-CAB), was released and approved for use in H.
pylori eradication in Japan. Although PPIs decrease gastric
acid secretion by inhibiting Hþ, Kþ-ATPase in parietal cells, P-
CABs do this by directly inhibiting Hþ-Kþ exchange on the
gastric luminal surface. Vonoprazan suppresses gastric acid
secretion through this alternative mechanism [6].
Recently, the superiority of vonoprazan over lansoprazole
for primary H. pylori eradication therapy was reported, with
an eradication rate of 93% for vonoprazan and 76% with lan-
soprazole (p < 0.01) [7]. However, few reports are available
regarding the rate of eradication employing both PPIs and P-
CAB. The aim of this studywas to determine if this newP-CAB
shows superiority to existing PPIs for the primary eradication
of H. pylori in routine clinical practice.
Patients and methods
Study population
We retrospectively reviewed the medical records of 573
patients who underwent standard primary H. pylorieradication therapy at Haga Red Cross Hospital (Moka,
Japan) and Shinozaki Medical Clinic (Utsunomiya, Japan)
between April 2013 and July 2015. Abstracted data include
age, sex, H. pylori presence test used, prior PPI or vono-
prazan use, type of PPI or vonoprazan used for eradication,
EGD findings, and side effects. All patients underwent EGD
because the Japanese national health insurance system
requires the diagnosis of H. pylori gastritis by EGD prior to
performing an H. pylori presence test. Positive H. pylori
status was established by a rapid urease test, histology,
stool antigen test, serology (serum IgG), or 13C-urea breath
test (UBT). The degree of atrophy was endoscopically
evaluated based on the KimuraeTakemoto classification, in
which closed and open types correspond to mild and severe
atrophy, respectively [8]. The Institutional Review Board
approved this study.
Primary H. pylori eradication
Standard triple therapy in Japan includes clarithromycin
200 mg, amoxicillin 750 mg, and an acid suppression drug
[lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), eso-
meprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice
daily for 1 week. The choice of acid-suppressing drug was
made by the physician in charge. Data regarding vonopra-
zan have been gathered since its release in Japan in
February 2015. Based on previous favorable eradication
data using vonoprazan [7], its use has predominated since
early 2015. For the evaluation of successful eradication, a
UBT or stool antigen test was used at least 8 weeks after the
eradication period. The cut-off value for the UBT was
2.5&. Before the UBT, PPI or vonoprazan intake was sus-
pended for at least 2 weeks for a patient taking a PPI or
vonoprazan. Successful primary H. pylori eradication ther-
apy was determined by a negative UBT or stool antigen test.
The stool antigen test was mostly used for patients who had
undergone distal gastrectomy. The success rate of eradi-
cation was assessed by intention-to-treat (ITT) and per-
protocol (PP) analyses. Exclusion criteria for PP analysis
included: (1) patients who showed poor compliance (<
50%); and (2) patients who did not return to the clinic to
receive a UBT or stool antigen test for evaluating the results
of eradication therapy. All patients treated, but not
included in the PP analysis, were considered to have failed
eradication.
Statistical analysis
Statistical analysis was performed using BellCurve for Excel
2015 software (Social Survey Research Information Co., Ltd.
Tokyo, Japan). Categorical data were assessed using
Fisher’s exact test. Differences in data with p < 0.05 are
considered statistically significant.
Table 1 Demographic data and endoscopic findings.
Number Total LAC RAC EAC VAC
573 198 138 120 117
Age (y), mean  SD 63.5  12.1 62.7  12.4 63.7  11.0 65.1  10.9 63.0  13.7
Gender, male 286 (50) 88 (44) 70 (51) 74 (62) 54 (46)
Prior PPI or vonoprazan use 192 (34) 68 (34) 37 (27) 43 (36) 44 (38)
Endoscopic findings
Reflux esophagitis, LA grade A/B/C/D 18/6/1/0 5/1/0/0 8/2/0/0 2/2/0/0 3/1/1/0
Gastric ulcer/scar 68 (12) 21 (11) 13 (9) 24 (20) 10 (9)
Duodenal ulcer/scar 54 (9) 18 (9) 12 (9) 13 (11) 11 (9)
Gastric hyperplastic polyp 63 (11) 22 (11) 12 (9) 17 (14) 12 (10)
Atrophic changea
Mild 102 (18) 44 (23) 24 (18) 13 (11) 21 (18)
Severe 460 (82) 149 (77) 109 (82) 107 (89) 95 (82)
Status post distal gastrectomy 11 (2) 5 (3) 5 (4) 0 (0) 1 (1)
Side effects 38 (7) 21 (11) 8 (6) 3 (3) 6 (5)
Per-protocol 549 (96) 189 (95) 132 (96) 114 (95) 114 (97)
Confirming successful eradication using UBT/stool antigen test 533/16 183/6 127/5 114/0 109/5
Data are presented as n (%) unless otherwise indicated.
EAC Z esomeprazole-based regimen; LA Z Los Angeles; LAC Z lansoprazole-based regimen; PPI Z proton pump inhibitor;
RAC Z rabeprazole-based regimen; SD Z standard deviation; VAC Z vonoprazan-based regimen; UBT Z 13C-urea breath test.
a Patients status post distal gastrectomy were excluded.
Intention-to-treat analysis
(n = 573)
Lost to follow up (n = 20)
Poor compliance (< 50%)
due to side effect (n = 4)
Per-protocol analysis
(n = 549)
Figure 1. Study flowchart.
Table 2 Comparison of vonoprazan and proton pump
inhibitors for eradication of Helicobacter pylori.
Total LAC RAC EAC VAC
ITT analysis (%) 73 66 67 83* 83*
(95% CI) (69e77) (59e72) (58e74) (75e89) (75e89)
n 419/573 131/198 92/138 99/120 97/117
PP analysis (%) 76 69 70 87* 85*
(95% CI) (73e80) (62e76) (61e77) (79e93) (77e91)
n 419/549 131/189 92/132 99/114 97/114
* p < 0.01 compared with LAC or RAC groups.
CIZ confidence interval; EACZ esomeprazole-based regimen;
ITT Z intention-to-treat analysis; LAC Z lansoprazole-based
regimen; PPZ per-protocol analysis; RACZ rabeprazole-based
regimen; VAC Z vonoprazan-based regimen.
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Clinical characteristics
Baseline characteristics and endoscopic data of the pa-
tients in each group are shown in Table 1. The mean age
among all patients was 64 years. More than 80% of patients
had severe gastric atrophy on endoscopy. The proportion of
patients with PP treatment was comparatively high (96%;
Figure 1). Side effects were observed in 7% of patients,
including bitter taste, diarrhea, and skin rash.
Success rate of primary H. pylori eradication
The overall rate of successful eradication was 73% (419/
573) in ITT analysis and 76% (419/549) in PP analysis (Table
2). The VAC group had a significantly superior eradication
rate compared with the LAC and RAC groups, and had a
similarly high eradication rate to the EAC group.A lower eradication rate in patients with severe atrophy
has been reported compared with patients with mild atrophy
[9]. Based on the degree of gastric atrophy, eradication rates
amongthefourpatientgroupswerecomparedafterexcluding
11 patients whowere status post distal gastrectomy. The VAC
group had the highest rate of eradication for patients with
mild gastric atrophy among the four groups, although not a
significant difference (Figure 2A). In patients with severe
gastric atrophy, both the VAC and EAC groups had a signifi-
cantly higher eradication rate than the LAC and RAC groups
(p < 0.01; Figure 2B). Only vonoprazan had a > 80% eradica-
tion rate inpatientswithbothmildand severegastricatrophy.Discussion
The eradication rate of H. pylori using VAC was significantly
higher than with LAC and RAC, in both ITT and PP analyses,
and showed a similar rate to EAC. In patients with severe
atrophy in this study, LAC and RAC groups had a significantly
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Figure 2. Eradication rate in patients with (A) mild gastric
atrophy and (B) severe gastric atrophy. Figures for each regimen
show the number of patients. * p < 0.01 compared with LAC
and RAC groups. EAC Z esomeprazole-based regimen;
ITT Z intention-to-treat analysis; LAC Z lansoprazole-based
regimen; PPZ per-protocol analysis; RACZ rabeprazole-based
regimen; VACZ vonoprazan-based regimen.
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but not in patients with mild atrophy. Furthermore, only
VAC had a > 80% eradication rate regardless of the degree
of atrophy. The strong acid inhibition by vonoprazan and
esomeprazole may have contributed to the observed in-
crease in the rate of successful primary H. pylori
eradication.
In this study, the VAC group had a favorable eradication
rate in spite of increasing antibiotic resistance in Japan
over the past decade [10]. The clinical effect of acid-
suppressing drugs was evaluated by the duration and de-
gree of acid inhibition [11]. Sugimoto et al. [12] reported
that sustained gastric pH > 4.0 was important for successfulH. pylori eradication. Vonoprazan acts by inhibition of the
Hþ, Kþ-ATPase pathway, with competitive and sustained
blockade, and provides rapid elevation of intragastric pH
[6]. The Japanese randomized prospective study reported
that a vonoprazan-based regimen was superior to the same
lansoprazole-based regimen (93% vs. 76%, p < 0.001) [7].
The difference (17%) in eradication rates in that study is
similar to the difference observed in the present study
(17%). Strong acid suppression through inhibition of the Hþ,
Kþ-ATPase pathway may at least partially explain this dif-
ference. Consistent with results reported in a meta-analysis
[5], the EAC group also had a similar superiority to the LAC
and RAC groups in this study. However, VAC did not show
superiority to EAC therapy. In a healthy volunteer study
using 24-hour pH monitoring, the acid-inhibitory effect of
vonoprazan was superior to that of esomeprazole [13].
Although the study used once daily doses of 20 mg vono-
prazan and 20 mg esomeprazole, twice daily 20 mg eso-
meprazole is used in H. pylori eradication therapy and may
provide adequate acid suppression for H. pylori eradica-
tion. Kagami et al. [14] recently reported that a difference
in the median pH  4 holding time ratio between vono-
prazan 20 mg twice daily and esomeprazole 20 mg twice
daily was only 9%. Therefore, the small difference in acid-
inhibitory effect in the twice daily models comparing
vonoprazan and esomeprazole may explain the similar
success rate of eradication.
The variation in acid inhibition by PPI is associated with
CYP2C19 genotypes, but CYP3A4 is mainly responsible for
the metabolism of vonoprazan. Thus, vonoprazan maintains
high pH levels in gastric glands even in CYP2C19 rapid
metabolizers [15]. In addition, the inhibitory effect of
vonoprazan (pKa 9.4) on gastric acid secretion is largely
unaffected by ambient pH, as it accumulates in the parietal
cells under both acidic and neutral conditions [16,17]. An-
tibiotics are more stable in a less-acidic environment and
induce higher antibiotic sensitivity in bacteria, leading to
high efficacy of eradication [18,19]. It has also been re-
ported that twice-daily dosing of esomeprazole also inhibits
acid secretion, even in CYP2C19 rapid metabolizers,
compared with twice-daily rabeprazole or lansoprazole
[20]. Esomeprazole leads to a steadily high pH sufficient to
eradicate H. pylori, but the use of rabeprazole or lanso-
prazole leads to a pH that is less stable. These data suggest
that some patients treated with rabeprazole or lansopra-
zole may have relatively low intragastric pH during the
eradication period.
Gastric atrophy is a risk factor for gastric cancer that
increases with the progression of atrophy. Therefore, the
success rate of H. pylori eradication is important in pa-
tients with severe gastric atrophy. Recently, a lower erad-
ication rate in patients with severe atrophy compared with
those with mild atrophy has been reported [9]. This sug-
gests that severe atrophy is a risk for eradication failure. In
patients with severe atrophy in this study, LAC and RAC
groups had a significantly lower eradication rate compared
with EAC and VAC groups, but not in patients with mild
atrophy. Data from the EAC/VAC groups indicate that high
gastric pH may be necessary to eradicate H. pylori in pa-
tients with severe atrophy. The LAC and RAC groups may
have low pH, making it impossible to eradicate H. pylori in
the presence of severe atrophic changes. The precise
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reported recently [9]. We suggest four possible explana-
tions for these observations: (1) severe atrophy prolongs
gastric emptying that may cause deactivation of enteric-
coated tablets [21,22]. Unlike PPIs, vonoprazan is not sup-
plied as enteric-coated tablets; (2) unlike lansoprazole and
rabeprazole, esomeprazole can maintain gastric pH > 5
even in patients who have the extensive metabolizer of
CYP2C19 genotype [20]; (3) there may be instability of
lansoprazole or rabeprazole in the secretory vesicles of
parietal cells or the presence of fewer parietal cells in
patients with severe atrophic changes; and (4) because
serum anti-H. pylori titers reflecting bacterial proliferation
are inversely correlated to the extent of intestinal meta-
plasia, H. pylori proliferation may be decreased in patients
with severe gastric atrophy resulting in low susceptibility to
antibiotics [23].
Some advantages of this study were that the treatment
regimens were homogeneous, and complete EGD findings
were available for all patients as well as extensive follow
up. All patients were treated with the same dose of clari-
thromycin and amoxicillin for the same duration. The
availability of endoscopic findings for all patients enabled
analysis of the relationship between successful eradication
and the degree of atrophy. However, there are some
acknowledged limitations to this study. ITT and PP analysis
were performed in a retrospective, nonrandomized, non-
control study. Antibiotic resistance and CYP2C19 expression
were not evaluated. The time frame for the eradication
period in the VAC group was different from patients
receiving existing PPIs because vonoprazan was released in
February 2015 in Japan. Three regimens (LAC, RAC, and
EAC) were used in 2013e2015 and one regimen (VAC) was
begun in 2015. Because clarithromycin resistance has been
increasing recently [3,24], there may be a higher rate of
resistance in 2015 than in 2013e2014. In this study, the VAC
group may be at a disadvantage compared with patients
receiving existing PPIs. These factors may limit the ability
to generalize the conclusions of this study, and these
retrospective data have to be carefully interpreted.
In conclusion, treatment with the VAC regimen had a
significantly higher H. pylori eradication rate than the LAC
and RAC regimens, and a similar eradication rate as the EAC
regimen. Severe gastric atrophy makes H. pylori eradica-
tion difficult in patients treated with LAC and RAC regi-
mens, however, the eradication rate is not affected by the
degree of atrophy in patients receiving the VAC regimen.
Future large prospective studies are necessary to confirm
these conclusions.References
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